No serious safety events related to the vaccine have been confirmed and it was well tolerated across both dosing regimens, it said. On Nov 16, US-based Moderna Inc said its experimental vaccine proved to be 94.5% effective based on an early data analysis. Russia's Sputnik-V vaccine on Nov. 11 was also shown to be more than 90% effective, though only based on 20 infections. PROFESSOR ANDREW POLLARD, DIRECTOR OF THE OXFORD VACCINE GROUP AND CHIEF INVESTIGATOR OF THE OXFORD VACCINE TRIAL"These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.

Source: bd News24 November 23, 2020 07:18 UTC